Target DPP4/Cav1 interaction in the treatment of diabetes and metabolic diseases
The team has a long-term relationship with Tabomedex and Calira, which are the leaders in the field
A clinical stage company, developing tegavivint, a novel, potent and selective nuclear β-catenin inhibitor to treat cancers.
Iterion Therapeutics, Inc.
Mining the full potential of drugs
Developing a platform to discover novel biased drugs with an improved therapeutic index
Provide first-in-class and best-in-class drugs for patients with organ fibrosis
Focus on studying the role and mechanism of myofibroblasts in fibrotic diseases
Therapeutic proteins engineered for super-affinity to the extracellular matrix improve tissue regeneration.
MorphoGene specializes in re-engineering growth factors with a high affinity ECM binding domain for better local retention and efficacy in the treatment of chronic wounds such as non-healing bone fractures, diabetic skin wounds, and ischemia.
Developing allosteric/uncompetitive phosphatase inhibitors for several protein tyrosine phosphatase (PTP)s.
Leveraging a novel brain drug delivery platform technology
Developing a peptide initially derived from the target sequence that can bind with neuronal nicotinic acetylcholin (nAch) receptor and mediate BBB crossing
Accelerating neuroscience drug discovery by going inside the cell for new protein targets
Path Therapeutics’ platform technology lifts the hood of the cell and identifies novel targets that can be purchased to jump-start stalled drug discovery programs